The estimated Net Worth of Bradley S. Galer is at least $4.96 Million dollars as of 15 March 2021. Bradley Galer owns over 5,218 units of Zogenix Inc stock worth over $593,843 and over the last 11 years he sold ZGNX stock worth over $0. In addition, he makes $4,367,010 as Executive Vice President and Chief Medical Officer at Zogenix Inc.
Bradley has made over 6 trades of the Zogenix Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,218 units of ZGNX stock worth $139,216 on 15 March 2021.
The largest trade he's ever made was exercising 10,000 units of Zogenix Inc stock on 25 June 2020 worth over $266,800. On average, Bradley trades about 1,196 units every 63 days since 2013. As of 15 March 2021 he still owns at least 22,258 units of Zogenix Inc stock.
You can see the complete history of Bradley Galer stock trades at the bottom of the page.
Dr. Bradley S. Galer M.D. serves as Executive Vice President, Chief Medical Officer of the Company. Dr. Galer has served as our Executive Vice President and Chief Medical Officer since December 2013. Prior to joining the company, Dr. Galer served as President of the Pain Group at Nuvo Research, Inc., a specialty pharmaceutical company with three commercialized topically delivered pain products from December 2009 to December 2013. In this position, he oversaw the strategy and operations of the Pain Group, including its commercialization, drug development activities, business development and licensing opportunities and liaising with partners. Prior to joining Nuvo, Dr. Galer was employed at Endo Pharmaceuticals Inc., as Senior Medical Officer and Group Vice President, Scientific Affairs from August 2002 to October 2005, where he was responsible for the departments of Clinical and Biostatistics, Medical Affairs, Pharmacovigilance, Medical Liaison and Medical Information. He and his team provided clinical and scientific leadership for the development and marketing of analgesic and migraine products, including Lidoderm, Percocet, Opana, Opana ER and Frova. Dr. Galer has also held numerous other industry positions, along with academic and clinical appointments. He has published over 200 articles on pain management in peer review journals and textbooks. Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Pain Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco, as well as headache training at Montefiore Headache Clinic in New York and University of California San Francisco.
As the Executive Vice President and Chief Medical Officer of Zogenix Inc, the total compensation of Bradley Galer at Zogenix Inc is $4,367,010. There are 1 executives at Zogenix Inc getting paid more, with Stephen Farr having the highest compensation of $10,346,800.
Bradley Galer is 57, he's been the Executive Vice President and Chief Medical Officer of Zogenix Inc since 2013. There are 9 older and 11 younger executives at Zogenix Inc. The oldest executive at Zogenix Inc is Cam Garner, 71, who is the Independent Chairman of the Board.
Bradley's mailing address filed with the SEC is 5858 Horton St #455, Emeryville, CA 94608, USA.
Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo, and Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: